Sign in or create an account to add this stock to your watchlist.
About Mirati Therapeutics (NASDAQ:MRTX)
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410
Debt
Debt-to-Equity RatioN/A
Current Ratio9.56
Quick Ratio9.56
Price-To-Earnings
Trailing P/E Ratio-15.95
Forward P/E Ratio-16.37
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.74 per share
Price / Book9.36
Profitability
EPS (Most Recent Fiscal Year)($2.78)
Net Income$-70,420,000.00
Net MarginsN/A
Return on Equity-62.28%
Return on Assets-55.07%
Miscellaneous
Employees51
Outstanding Shares29,050,000
Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions
What is Mirati Therapeutics' stock symbol?
Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."
How were Mirati Therapeutics' earnings last quarter?
Mirati Therapeutics Inc (NASDAQ:MRTX) posted its quarterly earnings results on Monday, May, 7th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.12. The biotechnology company earned $9.47 million during the quarter, compared to analysts' expectations of $10 million. View Mirati Therapeutics' Earnings History.
What price target have analysts set for MRTX?
10 equities research analysts have issued 1-year price targets for Mirati Therapeutics' shares. Their predictions range from $5.00 to $44.00. On average, they expect Mirati Therapeutics' stock price to reach $25.4444 in the next twelve months. View Analyst Ratings for Mirati Therapeutics.
What are Wall Street analysts saying about Mirati Therapeutics stock?
Here are some recent quotes from research analysts about Mirati Therapeutics stock:
- 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (5/9/2018)
- 2. Cann analysts commented, "Mirati Therapeutics, Inc. announced today that it has entered into an exclusive license agreement with BeiGene for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia (excluding Japan), Australia, and New Zealand. Mirati confirmed it will retain exclusive rights for the development, manufacturing and commercialization of sitravatinib for the rest of world." (1/8/2018)
Who are some of Mirati Therapeutics' key competitors?
Some companies that are related to Mirati Therapeutics include GW Pharmaceuticals (GWPH), FibroGen (FGEN), Hutchison China MediTech (HCM), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), TESARO (TSRO), Portola Pharmaceuticals (PTLA), Horizon Pharma (HZNP) and Emergent Biosolutions (EBS).
Who are Mirati Therapeutics' key executives?
Mirati Therapeutics' management team includes the folowing people:
- Dr. Rodney W. Lappe Ph.D., Exec. Chairman (Age 63)
- Dr. Charles M. Baum M.D., Ph.D., Chief Exec. Officer, Pres and Director (Age 60)
- Dr. James Christensen Ph.D., Chief Scientific Officer and Sr. VP (Age 50)
- Dr. Isan Chen M.D., Chief Medical & Devel. Officer and Exec. VP (Age 56)
- Mr. Jamie A. Donadio Ph.D., Chief Financial Officer and Sr. VP (Age 43)
Has Mirati Therapeutics been receiving favorable news coverage?
News articles about MRTX stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mirati Therapeutics earned a daily sentiment score of 0.11 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 47.50 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Mirati Therapeutics' major shareholders?
Mirati Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.19%), Point72 Asset Management L.P. (1.40%), PointState Capital LP (1.03%), Farallon Capital Management LLC (0.93%), Rock Springs Capital Management LP (0.65%) and Acuta Capital Partners LLC (0.34%). Company insiders that own Mirati Therapeutics stock include Boxer Capital, Llc, Bros Advisors Lp Baker, Charles M Baum, Jamie A Donadio, Jamie Christensen, Ltd Braslyn, Tuesday Thirteen Inc and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.
Which institutional investors are selling Mirati Therapeutics stock?
MRTX stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Citigroup Inc. and Federated Investors Inc. PA. Company insiders that have sold Mirati Therapeutics company stock in the last year include Jamie A Donadio, Jamie Christensen and Tuesday Thirteen Inc. View Insider Buying and Selling for Mirati Therapeutics.
Which institutional investors are buying Mirati Therapeutics stock?
MRTX stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., PointState Capital LP, Farallon Capital Management LLC, BlackRock Inc., Tibra Equities Europe Ltd, Iguana Healthcare Management LLC, UBS Group AG and Element Capital Management LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, Charles M Baum, Ltd Braslyn and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.
How do I buy shares of Mirati Therapeutics?
Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mirati Therapeutics' stock price today?
One share of MRTX stock can currently be purchased for approximately $44.35.
How big of a company is Mirati Therapeutics?
Mirati Therapeutics has a market capitalization of $1.13 billion. The biotechnology company earns $-70,420,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Mirati Therapeutics employs 51 workers across the globe.
How can I contact Mirati Therapeutics?
Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]
MarketBeat Community Rating for Mirati Therapeutics (MRTX)
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Mirati Therapeutics (NASDAQ:MRTX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Mirati Therapeutics in the last 12 months. Their average twelve-month price target is $25.4444, suggesting that the stock has a possible downside of 42.63%. The high price target for MRTX is $44.00 and the low price target for MRTX is $5.00. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.90 | 2.90 | 2.89 | 2.88 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.4444 | $25.4444 | $14.75 | $13.7143 |
| Price Target Upside: | 42.63% downside | 26.46% downside | 14.24% downside | 22.08% downside |
Mirati Therapeutics (NASDAQ:MRTX) Consensus Price Target History
Mirati Therapeutics (NASDAQ:MRTX) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Mirati Therapeutics (NASDAQ:MRTX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Mirati Therapeutics (NASDAQ MRTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.86%
Institutional Ownership Percentage: 84.65%
Mirati Therapeutics (NASDAQ MRTX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/9/2018 | Jamie A Donadio | CFO | Sell | 12,100 | $35.00 | $423,500.00 | 12,100 |  |
| 3/1/2018 | Jamie A Donadio | CFO | Sell | 51,875 | $27.13 | $1,407,368.75 | 9,375 | |
| 2/6/2018 | Jamie Christensen | SVP | Sell | 23,000 | $30.00 | $690,000.00 | 10,877 | |
| 1/26/2018 | Jamie Christensen | SVP | Sell | 12,500 | $26.11 | $326,375.00 | 15,377 | |
| 1/16/2018 | Jamie Christensen | SVP | Sell | 10,814 | $27.00 | $291,978.00 | 13,691 | |
| 1/11/2018 | Jamie Christensen | SVP | Sell | 14,725 | $22.99 | $338,527.75 | 6,395 | |
| 11/16/2017 | Jamie Christensen | SVP | Sell | 10,275 | $18.00 | $184,950.00 | 12,670 | |
| 11/16/2017 | Venbio Select Advisor Llc | Major Shareholder | Buy | 650,000 | $13.00 | $8,450,000.00 | | |
| 11/2/2017 | Jamie Christensen | SVP | Sell | 7,499 | $14.00 | $104,986.00 | 10,169 | |
| 10/4/2017 | Jamie Christensen | SVP | Sell | 4,000 | $14.00 | $56,000.00 | | |
| 9/21/2017 | Tuesday Thirteen Inc. | Major Shareholder | Sell | 1,000 | $10.65 | $10,650.00 | | |
| 9/15/2017 | Jamie Christensen | SVP | Sell | 770 | $12.00 | $9,240.00 | | |
| 1/26/2017 | Ltd. Braslyn | Major Shareholder | Buy | 48,169 | $5.45 | $262,521.05 | | |
| 1/25/2017 | Ltd. Braslyn | Major Shareholder | Buy | 30,600 | $5.42 | $165,852.00 | | |
| 1/24/2017 | Ltd. Braslyn | Major Shareholder | Buy | 27,682 | $5.32 | $147,268.24 | | |
| 1/23/2017 | Ltd. Braslyn | Major Shareholder | Buy | 19,251 | $5.27 | $101,452.77 | | |
| 1/20/2017 | Ltd. Braslyn | Major Shareholder | Buy | 61,158 | $5.46 | $333,922.68 | | |
| 1/17/2017 | Ltd. Braslyn | Major Shareholder | Buy | 119,887 | $5.50 | $659,378.50 | | |
| 1/6/2017 | Boxer Capital, Llc | Major Shareholder | Buy | 286,163 | $5.60 | $1,602,512.80 | | |
| 6/14/2016 | Charles M Baum | CEO | Buy | 20,000 | $7.05 | $141,000.00 | 48,556 | |
| 6/9/2016 | Bros. Advisors Lp Baker | Major Shareholder | Sell | 999,358 | $9.41 | $9,403,958.78 | 137 | |
| 6/7/2016 | Ltd. Braslyn | Major Shareholder | Buy | 376,902 | $9.96 | $3,753,943.92 | | |
| 5/6/2016 | Ltd. Braslyn | Major Shareholder | Buy | 65,782 | $18.21 | $1,197,890.22 | | |
| 3/28/2016 | Ltd. Braslyn | Major Shareholder | Buy | 20,848 | $19.36 | $403,617.28 | | |
| 3/18/2016 | Ltd. Braslyn | Major Shareholder | Buy | 1,166 | $19.34 | $22,550.44 | | |
| 1/15/2016 | Mark J. Gergen | COO | Sell | 10,000 | $25.92 | $259,200.00 | 5,748 | |
| 9/16/2015 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 150,000 | $45.00 | $6,750,000.00 | | |
| 5/26/2015 | Jamie Christensen | SVP | Sell | 4,750 | $28.07 | $133,332.50 | | |
| 3/5/2015 | Jamie Christensen | SVP | Sell | 6,000 | $25.41 | $152,460.00 | | |
| 2/19/2015 | Jamie Christensen | SVP | Sell | 4,750 | $22.84 | $108,490.00 | | |
| 2/3/2015 | Orbimed Advisors Llc | Major Shareholder | Buy | 100,000 | $20.00 | $2,000,000.00 | | |
| 1/29/2015 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 425,000 | $20.00 | $8,500,000.00 | | |
| 7/1/2014 | Orbimed Advisors Llc | Major Shareholder | Sell | 107,332 | $21.66 | $2,324,811.12 | | |
| 11/26/2013 | Charles M Baum | CEO | Buy | 5,000 | $16.96 | $84,800.00 | | |
| 10/29/2013 | Orbimed Advisors Llc | Major Shareholder | Buy | 125,000 | $17.50 | $2,187,500.00 | | |
| 10/24/2013 | Tang Capital Partners Lp | Major Shareholder | Buy | 57,143 | $17.50 | $1,000,002.50 | | |
| 9/20/2013 | Tang Capital Partners Lp | Major Shareholder | Sell | 36,898 | $16.34 | $602,913.32 | | |
(Data available from 1/1/2013 forward)
Mirati Therapeutics (NASDAQ MRTX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Brokers Offer Predictions for Mirati Therapeutics Inc's Q2 2018 Earnings (MRTX)
www.americanbankingnews.com - May 11 at 8:34 AM |
| Jefferies Group Equities Analysts Increase Earnings Estimates for Mirati Therapeutics Inc (MRTX)
www.americanbankingnews.com - May 10 at 9:36 AM |
| Q2 2018 EPS Estimates for Mirati Therapeutics Inc (MRTX) Cut by Analyst
www.americanbankingnews.com - May 10 at 6:36 AM |
| Q2 2018 EPS Estimates for Mirati Therapeutics Inc Cut by SunTrust Banks (MRTX)
www.americanbankingnews.com - May 10 at 6:36 AM |
| SunTrust Banks Comments on Mirati Therapeutics Inc's FY2022 Earnings (MRTX)
www.americanbankingnews.com - May 9 at 9:47 AM |
| Mirati Therapeutics (MRTX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 8:52 AM |
| Mirati Therapeutics (MRTX) Announces Quarterly Earnings Results, Beats Estimates By $0.12 EPS
www.americanbankingnews.com - May 8 at 10:28 AM |
 | Mirati Therapeutics Reports First Quarter Financial Results
finance.yahoo.com - May 7 at 5:37 PM |
| Mirati: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 5:37 PM |
| Mirati Therapeutics Inc (MRTX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 6 at 10:19 AM |
| Contrasting Mirati Therapeutics (MRTX) & Eyenovia (EYEN)
www.americanbankingnews.com - May 5 at 11:23 AM |
| Mirati Therapeutics (MRTX) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - May 5 at 12:11 AM |
| Equities Analysts Set Expectations for Mirati Therapeutics Inc's Q1 2018 Earnings (MRTX)
www.americanbankingnews.com - May 3 at 6:57 AM |
| ValuEngine Upgrades Mirati Therapeutics (MRTX) to Strong-Buy
www.americanbankingnews.com - May 2 at 11:38 PM |
| Can These Top-Performing Biotech Stocks Keep Climbing?
finance.yahoo.com - April 30 at 5:14 PM |
 | Mirati Therapeutics (MRTX) Reports Progress Of Lead Programs, Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
www.streetinsider.com - April 25 at 5:28 PM |
| Mirati Therapeutics Target of Unusually High Options Trading (MRTX)
www.americanbankingnews.com - April 25 at 7:36 AM |
| Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
finance.yahoo.com - April 24 at 5:35 PM |
| Mirati Therapeutics, Inc. (MRTX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 11 at 8:33 AM |
| Mirati Therapeutics (MRTX) Receives Buy Rating from SunTrust Banks
www.americanbankingnews.com - April 8 at 2:04 PM |
| Mirati Therapeutics (MRTX) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - April 3 at 11:39 AM |
| Mirati Therapeutics (MRTX) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 1 at 5:22 PM |
| Mirati Therapeutics' (MRTX) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - April 1 at 2:38 PM |
| Mirati Therapeutics (MRTX) PT Set at $18.00 by Oppenheimer
www.americanbankingnews.com - March 30 at 12:34 PM |
| HC Wainwright Boosts Mirati Therapeutics (MRTX) Price Target to $21.00
www.americanbankingnews.com - March 30 at 12:56 AM |
| Mirati Therapeutics (MRTX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 29 at 11:28 AM |
| Mirati Therapeutics (MRTX) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 28 at 12:00 AM |
| Mirati Therapeutics (MRTX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 17 at 8:22 PM |
| Mirati Therapeutics, Inc. (MRTX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 17 at 9:48 AM |
| Mirati Therapeutics, Inc. (MRTX) Expected to Post Quarterly Sales of $10.00 Million
www.americanbankingnews.com - March 17 at 7:10 AM |
 | Mirati Therapeutics (MRTX) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
seekingalpha.com - March 16 at 6:29 PM |
| Mirati Therapeutics (MRTX) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 6:11 PM |
| Jamie A. Donadio Sells 12,100 Shares of Mirati Therapeutics, Inc. (MRTX) Stock
www.americanbankingnews.com - March 13 at 7:53 PM |
 | 32 Stocks Moving In Monday's Mid-Day Session | Benzinga - Benzinga
www.benzinga.com - March 13 at 8:26 AM |
| UPDATE: Barclays Starts Mirati Therapeutics, Inc. (MRTX) at Overweight - StreetInsider.com
www.streetinsider.com - March 13 at 8:26 AM |
| Traders Purchase Large Volume of Call Options on Mirati Therapeutics (MRTX)
www.americanbankingnews.com - March 13 at 7:28 AM |
| Mirati Therapeutics (MRTX) Research Coverage Started at Barclays
www.americanbankingnews.com - March 12 at 10:28 PM |
| Mirati Therapeutics (MRTX) Price Target Increased to $40.00 by Analysts at HC Wainwright
www.americanbankingnews.com - March 12 at 2:18 PM |
| Research Analysts Issue Forecasts for Mirati Therapeutics, Inc.'s Q3 2018 Earnings (MRTX)
www.americanbankingnews.com - March 12 at 4:00 AM |
| Mirati Therapeutics (MRTX) PT Raised to $40 at SunTrust Robinson Humphrey
www.streetinsider.com - March 10 at 6:23 PM |
| SunTrust Banks Raises Mirati Therapeutics (MRTX) Price Target to $40.00
www.americanbankingnews.com - March 9 at 9:02 PM |
| Did Mirati Therapeutics Inc’s (NASDAQ:MRTX) Recent Earnings Growth Beat The Trend?
finance.yahoo.com - March 9 at 6:49 PM |
| Mirati Therapeutics (MRTX) Posts Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - March 9 at 4:11 PM |
 | Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - March 8 at 6:42 PM |
| Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results
finance.yahoo.com - March 8 at 6:42 PM |
| Mirati Therapeutics To Present At Upcoming Healthcare Conferences - PR Newswire (press release)
www.prnewswire.com - March 8 at 8:24 AM |
| Royce & Associates LP Sells 130,000 Shares of Mirati Therapeutics, Inc. (MRTX)
www.americanbankingnews.com - March 6 at 10:53 AM |
| Citigroup Boosts Mirati Therapeutics (MRTX) Price Target to $37.00
www.americanbankingnews.com - March 5 at 2:59 PM |
| Bogle Investment Management L P DE Acquires Shares of 137,671 Mirati Therapeutics, Inc. (MRTX)
www.americanbankingnews.com - March 5 at 5:10 AM |
| Mirati Therapeutics, Inc. (MRTX) CFO Jamie A. Donadio Sells 51,875 Shares
www.americanbankingnews.com - March 2 at 9:23 PM |
Mirati Therapeutics (NASDAQ:MRTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Mirati Therapeutics (NASDAQ:MRTX) Income Statement, Balance Sheet and Cash Flow Statement
Mirati Therapeutics (NASDAQ MRTX) Stock Chart for Saturday, May, 26, 2018
Loading chart…
